0001209191-18-009413.txt : 20180212
0001209191-18-009413.hdr.sgml : 20180212
20180212210007
ACCESSION NUMBER: 0001209191-18-009413
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180209
FILED AS OF DATE: 20180212
DATE AS OF CHANGE: 20180212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Turner Heather D
CENTRAL INDEX KEY: 0001403571
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36548
FILM NUMBER: 18598782
MAIL ADDRESS:
STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 160
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001604464
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 460920988
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD
STREET 2: SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-278-8930
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD
STREET 2: SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-09
1
0001604464
Atara Biotherapeutics, Inc.
ATRA
0001403571
Turner Heather D
C/O ATARA BIOTHERAPEUTICS, INC.
611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Former EVP, GC & Sec.
Common Stock
2018-02-09
4
S
0
4596
36.63
D
77112
D
Common Stock
2018-02-09
4
S
0
4123
37.38
D
72989
D
Common Stock
2018-02-09
4
S
0
600
38.63
D
72389
D
Common Stock
2018-02-09
4
S
0
733
39.66
D
71656
D
Common Stock
2018-02-09
4
S
0
600
40.62
D
71056
D
Common Stock
2018-02-09
4
S
0
1562
41.69
D
69494
D
Transaction pursuant to Rule 10b5-1 Plan adopted September 23, 2016.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.00 to $37.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.05 to $38.05. The reporting person will provide to the
issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $39.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $39.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.20 to $41.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.35 to $41.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
/s/ David Tucker, Attorney-in-Fact for Heather D. Turner
2018-02-12